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Abstract 13 
This work demonstrates the preparation, structural characterization, and the kinetics of the 14 
drug release of hyaluronic acid (HyA)-based colloidal drug delivery systems which contain 15 
hydrophobic ketoprofen (KP) as model molecule. Because of the highly hydrophilic character 16 
of HyA the cross-linked derivatives at different cross-linking ratio have been synthesized. The 17 
hydrophobized variants of HyA have also been produced by modifying the polymer chains 18 
with cetyltrimethylammonium bromide (CTAB) at various HyA/CTAB ratios. Due to 19 
modifications the coherent structure of HyA changes into an incoherent colloidal system that 20 
were verified by rheological investigations. Nearly 70% of the encapsulated KP dissolve from 21 
the totally cross-linked HyA carrier but the release rate of KP is about 20% (after 8h) from the 22 
CTAB-modified colloidal system at HyA monomer/CTAB 1:0.8 mass ratio. It has been 23 
verified that the modified HyA may be a potential candidate for controlled drug release of 24 
hydrophobic KP molecules.  25 
 26 
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1. Introduction  29 
All areas encapsulating nano- or microparticle-based drug delivery systems have 30 
become some of the most fascinating research areas in modern pharmaceutical development. 31 
Several biodegradable macromolecules such as polyesters, proteins, polysaccharides, 32 
polyelectrolytes, lipids etc. (Benkő et al., 2015; Csapó et al., 2016; Danhier et al., 2012; 33 
Kumari et al., 2010; Padilla et al., 2002; Palumbo et al., 2006; Pasqui et al., 2012), or 34 
inorganic materials (layer double hydroxides (LDH), clays, mesoporous silica etc. (Deák et 35 
al., 2018; Varga, Benko, Sebok, Bohus, et al., 2014) are used as drug carriers in order to 36 
achieve a targeted drug delivery system and also a controlled drug release process. Generally, 37 
albumin proteins, biocompatible polymers, liposomes, or solid lipid NPs have been utilized 38 
for encapsulation of non-steroidal anti-inflammatory drugs (NSAID) such as ibuprofen, 39 
meloxicam etc. (Benkő et al., 2015; Csapó et al., 2016; Varga et al., 2014). Ketoprofen (KP) 40 
also belongs to NSAID and is widely used to treat postoperative pain, including patients after 41 
a gastric resection.  42 
 Hyaluronic acid (HyA) is a well-known linear polysaccharide of alternating units of β-43 
1,4-D-glucuronic acid and β-1,3-N-acetyl-D-glucosamine. (Berkó et al., 2013; Bodnár et al., 44 
2009; Hashad et al., 2017; Lee et al., 2015; Maroda et al., 2011; Wang et al., 2017) Because 45 
of the biocompatible, biodegradable, non-toxic, non-immunogenic and non-inflammatory 46 
features this biomaterial is an ideal candidate for several medical and pharmaceutical 47 
applications. At physiological conditions (pH, ionic strength) the HyA molecules have a 48 
negative charge (hyaluronate form) which results in an extremely high hydrophilic property. 49 
Thanks to the hydrophilic character of HyA it is present in several biological fluids, the 50 
highest amount can be found in the extracellular matrix of the soft connective tissues. The 51 
main disadvantage of this hydrophilic character is that HyA molecules, without chemical 52 
structural modification, cannot be simply used as a carrier. In most cases chemical preparation 53 
routes have been selected in order to synthesize the hydrophobized derivatives of HyA (e.g. 54 
biocompatible polymer (HyA/polylactic acid (Mayol et al., 2014)) or different alkyl- and aryl-55 
functionalized derivatives (HyA/decylamine(DA)) (Lee et al., 2015; Vafaei et al., 2016). 56 
Some cases the HyA has been used as surface functionalizing agent for preparation of e.g. 57 
core-shell type NPs (HyA/Human serum albumin-covered chitosan NPs) via electrostatic 58 
adsorption of the negatively charged HyA onto the surface of core NPs which has a positive 59 
surface charge (Hashad et al., 2017). Besides these derivatives the cross-linked variants of 60 
HyA can also be used to encapsulate different drugs (Berkó et al., 2013; Bodnár et al., 2009; 61 
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Maroda et al., 2011). Various techniques have been developed for the production of cross-62 
linked HyA, but one of the commonly used method is the carbodiimde technique. (Bodnár et 63 
al., 2009; Maroda et al., 2011) During this procedure the covalent cross-linking of the 64 
carboxyl functional groups of HyA molecules is carried out with a diamine in an aqueous 65 
medium at room temperature. The main advantage of this technique is that stable colloidal 66 
particles can be formed in water without the use of any surfactant or other organic solvent. 67 
Another possibility is the chemical modification of the HyA molecules by linking aliphatic or 68 
aromatic functional groups to the previously mentioned carboxyl moiety which gives the HyA 69 
macromolecules hydrophobicity.(Choi et al., 2009) Moreover, the less-known neutralization 70 
of HyA via the formation of electrostatic interactions using positively charged amines 71 
containing long aliphatic chains like cetyltrimethylammonium bromide (CTAB) also results 72 
in HyA particles having hydrophobic nature. (Kargerová et al., 2014; Oueslati et al., 2014; 73 
Sauerová et al., 2015) In previous work by other research groups, the KP was encapsulated in 74 
different polymers (e.g. poly (D, L-lactic acid) (PDLLA) or Eudragit) or alginate and gelatin-75 
based carriers but the HyA has not been used before for the direct encapsulation of KP 76 
molecules. (Arida & Al-Tabakha, 2007; Del Gaudio, Russo, Rosaria Lauro, Colombo, & 77 
Aquino, 2009; Vučen et al., 2013) 78 
In this work hydrophobic KP, as the model drug molecule, has been used to develop 79 
and characterize different types of modified HyA-based systems for controlled drug release. 80 
The cross-linking of HyA has been carried out in aqueous media at different ratios of cross-81 
linking (50; 75 and 100%). Moreover, the hydrophobized derivatives of HyA have also been 82 
prepared by using CTAB at three different HyA monomer/CTAB mass ratios (1:0.2; 1:0.5; 83 
1:0.8). Besides structural characterizations the drug release process has also been investigated 84 
and the experimental results of different colloidal systems were interpreted. One of the main 85 
motivation of this work was to introduce that the extreme hydrophilic HyA after structural 86 
modifications is applicable for encapsulation of highly hydrophobic KP small molecules 87 
which results in the formation of an effective HyA-based nanosized colloidal systems and a 88 
controlled KP release is also feasible.   89 
2. Materials and Methods 90 
2.1 Materials 91 
 Hyaluronic acid sodium salt (HyA, 200-500 kDa) was obtained from Gedeon Richter 92 
Plc. Ketoprofen (KP; C16H14O3; ≥98%) and CTAB (CH3(CH2)15N(Br)(CH3)3; 95%), sodium 93 
phosphate dibasic dodecahydrate (Na2HPO4×12H2O; 98.5%) and sodium phosphate 94 
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monobasic monohydrate (NaH2PO4×H2O; ≥99%) were purchased from Sigma-Aldrich. 95 
Sodium chloride (NaCl; a.r.), from Molar Chemicals, was used to prepare isotonic (150 mM) 96 
NaCl solution. For the cross-linking reaction 2,2’(ethylenedioxy)bis(ethylamine) (EDEA; 97 
NH2CH2CH2OCH2CH2OCH2CH2NH2; 98%) and 1-[3-(dimethylamino)propyl]-3-98 
ethylcarbodiimid methiodide (EDC methiodide; C2H5N=C=N(CH2)3N(CH3)3I) were obtained 99 
from Sigma-Aldrich. Highly purified water was obtained by deionization and filtration with a 100 
Millipore purification apparatus (18.2 MΩ·cm at 25 ºC). All solvents and reagents used were 101 
of analytical grade and no further purification were made.  102 
2.2 Experimental procedures of the HyA modifications 103 
Cross-linked (cl) HyA derivatives were prepared according to the previously published 104 
procedure reported by Bodnár et al.(Bodnár et al., 2009) The synthesis was performed at 105 
room temperature. Namely, 200 mg HyA was dissolved in water to produce 1 mg/mL solution 106 
then the pH was adjusted to pH = 5.5. The stoichiometric ratio of cross-linking was 50%, 75% 107 
and 100% resulting in cl-HyA/50%, cl-HyA/75% and cl-HyA/100% samples. Accordingly, 108 
1.88 mL, 2.82 mL and 3.76 mL EDEA solution (1 v/v%, pH = 5.5) was added to the HyA 109 
solution and mixed for 30 min. Then 80 mg, 120 mg and 160 mg EDC methiodide was 110 
dissolved in water and added to the mixture drop by drop, respectively. After an overnight 111 
stirring the product was purified by dialysis for 7 days against distilled water and the aqueous 112 
solution of the final product was freeze-dried. For CTAB modification different calculated 113 
amount of surfactant was added to the aqueous solution of HyA to change the hydrophobicity. 114 
The mixture was stirred for 30 min before further use.  115 
2.3 Preparation of KP-containing systems 116 
Because of the low solubility of KP in pure Milli-Q water (cmax = 0.051 mg/mL) all drug 117 
containing samples were prepared in phosphate buffer solution (PBS) at pH = 7.4 at 25 °C 118 
using constant ionic strength (0.9 % NaCl) which highly increased in the KP solubility (cKP = 119 
20 mg/mL). In all cases constant KP (cKP = 20 mg/mL) and constant HyA concentrations 120 
(100.0-100.0 mg lyophilized HyA and cl-HyA/mL) were used. The aqueous KP solutions 121 
were added to the different individual cl-HyA and HyA/CTAB samples which resulted in the 122 
formation of a gel-like structure after 24 h. After KP loading the samples were diluted to 0.1% 123 
and centrifuged (8000 rpm, 10 min). The supernatant contained only 4.5-5.0 % remained KP 124 
molecules determined by the previously registered spectrophotometric calibration curve. 125 
According to this determination method the loading efficiency is ca. 95.5-95.0%.  126 
127 
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 2.4 Methods for structural characterizations 128 
High-resolution transmission electron microscopy (HRTEM) images were recorded on a 129 
Tecnai G2 instrument at 200kV accelerating voltage and they were analyzed using ImageJ 130 
software. The particle size and zeta potential values were determined by dynamic light 131 
scatteing (DLS) with a Zetasizer Nano ZS ZEN 4003 apparatus (Malvern Ins., UK) equipped 132 
with a He-Ne laser (λ = 633 nm). The measurements were performed at 25 ± 0.1 °C, with an 133 
angle detection of 173° in a clear disposable zeta cell. In order to determine the maximum 134 
amount of CTAB to be added prior to precipitation 0.02 M of CTAB was added stepwise (20-135 
20 µL/ step) to 0.2 mg/mL concentration of HyA in PBS and the zeta potential values were 136 
registered with DLS. Turbidity measurements were performed by a Precision Bench Turbidity 137 
Meter LP2000 (Hanna Ins.), while the conductivity was measured by a Radelkis OK- 114 138 
conductometer equipped with an electrode with sheet plates. The Fourier transform infrared 139 
(FT-IR) spectroscopy studies were performed by using Jasco FT/IR-4700 spectrometer with 140 
ATR PRO ONE Single-reflection accessory (ABL&JASCO, Hungary). Spectra were 141 
registered at 4 cm
-1
 optical resolution by averaging 256 interferrograms.  142 
2.5 Isothermal Titration Calorimetry (ITC) studies 143 
Thermometric titration experiments were performed at 298.15 K with a computer-controlled 144 
VP-ITC power-compensation microcalorimeter (MicroCal) in order to determine the degree 145 
of the charge compensation of the CTAB in presence of HyA. Deionized water or HyA 146 
solution (1.4 mL) in the sample cell was titrated under constant stirring with 300 µL of CTAB 147 
solution in aliquots of 10 µL in periodic time intervals of 5 min. The enthalpograms 148 
(calorimeter power signal vs time) were evaluated by means of Origin Microcal 7.1. software. 149 
ITC curves were successfully ﬁtted by using the sigmoidal Boltzmann equation. The modiﬁed 150 
version of Boltzmann equation has been used to improve the precision of the determination of 151 
the critical micellization concentration (cmc).(Juhász et al., 2017; Kiraly et al., 2001)  152 
2.6 Rheological studies 153 
All rheological measurements were performed using an Anton Paar Physica MCR 301 154 
Rheometer (Anton Paar, GmbH, Germany) at 25.0±0.1 °C to provide concentration-155 
dependent structural information on the modified HyA-based drug carrier systems. The 156 
measuring system equipped with a 25 mm diameter parallel cone-plate geometry (CP25-1-157 
SN12204), a double-gap- (DG26.7-SN12740) and a concentric cylinder geometry (CC27-158 
SN12793). The rheometer utilized a temperature controlled water bath in combination with a 159 
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Peltier heating system for accurate control. Detailed parameters of the rheological 160 
measurements, as well as the evaluation process, are summarized in the Supplementary. 161 
2.7 In vitro drug release experiments 162 
The release rate of KP molecules was determined by spectrophotometric measurements 163 
detected the characteristic absorbance band of KP at 260 nm using a UV-1800 (Shimadzu) 164 
double beam spectrophotometer with a 1 cm quartz cuvette in the range of 200-500 nm. The 165 
in vitro drug release experiments were carried out in a phosphate buffer (PBS, pH = 7.4) at 25 166 
°C. A cellulose membrane (Sigma-Aldrich) was used as a dialysis membrane. The release 167 
process was followed for 480 min (8 h). Samples were taken every 10 minutes in the first 168 
hour and then once per hour. Analysis of in vitro drug release data helps evaluate the release 169 
kinetics and mechanism. Numerous mathematical models (zero-order, first-order, Weibull, 170 
Hixone-Crowell, Korsmeyere-Peppas, etc.) have been used to describe the release properties 171 
of the drug molecules (Costa et al., 2001; Peppas et al., 1977). The detailed description of the 172 
different kinetic models is summarized in Supplemetary.   To determine the value of the 173 
kinetic constants and other parameters of the applied release kinetic models, the sum of the 174 
square of differences between the measured and predicted concentration values have been 175 
minimalized using a spreadsheet based computer application for nonlinear parameter 176 
estimation (Juhász et al., 2016; Juhász, Csapó, Vécsei, & Dékány, 2017).  177 
3. Results and Discussion  178 
3.1 Structural characterization of the different HyA-based carriers  179 
Due to its highly hydrophilic nature, HyA as a possible carrier for encapsulation of 180 
hydrophobic agents requires structural modifications. Both the cross-linked (cross-linking 181 
ratio of 50, 75 and 100%) and hydrophobized derivatives (partly neutralization with 182 
positively-charged amines) of the HyA carrier have been successfully prepared.  FT-IR 183 
studies, which are in good agreement with the previously published data, (Barbucci et al., 184 
2002; Jiang et al., 2015) have been performed to identify the success of the formation of 185 
cross-linking, the results are presented in Fig.S1.  186 
 The different HyA modifiation methods are summarized in Scheme 1.  187 
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 188 
Scheme 1. Schematic representation of HyA modifications: cross-linking and neutralization 189 
with positively-charged amine. 190 
Due to structural modifications it was found that increasing cross-linking ratio from 50 % to 191 
100% results in the formation of nanosized particles, with an increasing size of ca. 45 nm (cl-192 
HyA/50%) and ca. 110 nm (cl-HyA/100%). Figure 1. shows the particle size distributions of 193 
cl-HyA carrier systems determined by DLS with a representative TEM image of the cl-194 
HyA/100% particles. The registered TEM image is in accord with the DLS results, the slight 195 
difference between the results can be explained by the hydrodynamic diameter. However the 196 
particle size increases with the cross-linking ratio, the presence of more polydispersed 197 
systems can be confirmed by DLS. In contrast, the measured Zeta-potential values at neutral 198 
pH (pH ~ 7.0) shows an increased stability (cl-HyA/50%: ζ = -13.8 ± 0.1 mV, cl-HyA/75%: ζ 199 
= -20.0 ± 2.1 mV, cl-HyA/100%: ζ = -23.6 ± 0.6 mV) for the application of higher 200 
concentration of cross-linker. For HyA/CTAB systems the structure, the charge, as well as the 201 
optimal ratio of HyA and CTAB, were determined by conductometric, turbidity, Zeta-202 
potential and ITC measurements in an aqueous solution at 25 °C. It is well known that the 203 
CTAB molecules are capable of forming micelles when the concentration reaches the cmc. 204 
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 205 
Figure 1. Particle size distribution of the different cl-HyA carriers determined by DLS (A) 206 
and a representative HRTEM image and particle size distribution of the cl-HyA/100% system 207 
(B). 208 
According to the parallel conductometric measurements 0.94 ± 0.01 mM of cmc value is 209 
obtained for CTAB (Figure 2A), while same 0.94 ± 0.01 mM value was determined by ITC 210 
as the grey continuous line represents on Fig. 3.B. 211 
212 
Figure 2. Determination of the cmc of CTAB by conductometric measurements in the 213 
absence (A) and in the presence (B) of HyA (cHyA= 0.1 mg/mL). 214 
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Both the conductometric and ITC studies have been carried out in the presence of 0.1 mg/mL 215 
of HyA and as Figure 2B and Figure 3B represent, the cmc value shifted to 1.16 ± 0.02 mM, 216 
respectively. 217 
218 
Figure 3. Calorimetric enthalpies of dilution obtained from ITC experiments for CTAB in the 219 
presence of HyA (cHyA = 0.1 mg/mL) at cCTAB = 12 mM (A) and cCTAB = 5 mM (B) at 298 K. 220 
The continuous grey lines in Fig. 3 represent the enthalpogram of pure CTAB in the absence 221 
of HyA under the same conditions. The degree of this shift (presence of excess CTAB) 222 
strongly depends on the total amount of HyA in the sample. Calculating with the HyA 223 
concentration we can conclude that the negatively charged HyA, before the formation of 224 
micelles, is totally neutralized by CTAB. At the neutralization point the CTAB/HyA 225 
monomer ratio is ca. 1:1 molar (0.96:1.0 mass ratio) obtained by conductometry and ITC 226 
studies. In order to determine the equivalent charge of the linear HyA, an additional ITC 227 
measurement was performed with diluted surfactant solution (cCTAB = 5 mM, cHyA = 0.1 228 
mg/mL). As can be seen in Figure 3A an inflection point is observed at 0.2 ± 0.01 mM which 229 
corresponds to nearly 1.2:1.0 surfactant/HyA monomer molar ratio. This observation also 230 
supports the equivalent charge compensation of HyA monomer with CTAB.  As Fig. 4 shows 231 
the Zeta potential of the negatively-charged polymer reaches the zero value at 0.95:1.0 232 
CTAB/HyA monomer mass ratio which is in accord with the conductometry, and ITC 233 
experiments.  Both the turbidity measurements and the change of the average particle 234 
diameter of the CTAB/HyA system confirm the aggregation of the polymer chains after the 235 
charge compensation of the carboxyl groups of HyA. 236 
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 237 
Figure 4. Zeta potential (A), turbidity and hydrodynamic diameter (B) of the HyA/CTAB 238 
system as a function of increasing CTAB/HyA monomer mass ratio (cHyA = 0.2 mg/mL) The 239 
(B) represents the photos of the samples before (at mCTAB/mHyA=0.2) and after (at 240 
mCTAB/mHyA=0.95) charge compensation of HyA. 241 
Above this surfactant concentration (0.95 mg CTAB/1.0 mg HyA monomer) the particle size 242 
rises dramatically (from 50 nm to ca. 750 nm) while the turbidity decreases due to the 243 
aggregation of the hydrophobized and neutralized polymer chains. The registered DLS curves 244 
of HyA/CTAB system at different mHyA/mCTAB ratios are presented in Fig. S2.  245 
3.2 Concentration-dependent rheological characterization of the aqueous HyA solutions 246 
and hydrogels before structural modifications 247 
Based on the rheological studies we found that, the increase in polymer concentration resulted 248 
in a dramatic change in the rheological behavior. The HyA solutions show Newtonian, non-249 
Newtonian and viscoelastic behavior as the concentration increases from 0.05 to 100 mg/mL. 250 
The viscosities of diluted and moderately concentrated polymer solutions were determined by 251 
a rotational technique based on the fitting of registered flow curves. In the case of much dilute 252 
solutions, the linear flow curves prove the validity of the Newton law (Figure S3). For these 253 
extremely diluted polymer solutions, which are usually considered as a molecular solution, 254 
the viscosity variations are associated with a behavior (deformation, orientation etc.) of 255 
separate molecules under flow conditions. Generally, the viscosities of moderately 256 
concentrated solutions of high-molecular weight polymers are known to be variable quantities 257 
which decrease with increasing shear rate. This shear-thinning effect has been understood for 258 
a long time and as Fig. S4 shows similar behavior was observed for HyA above 1.00 mg/mL 259 
concentration. In the case of these concentrated solutions, a varying viscosity is assumed to be 260 
due to the entanglement of linear polymer chains. An alternative explanation of this effect, is 261 
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based on an assumption of weak macromolecular cross-linking. These secondary bindings 262 
disappear and reappear again as a result of thermal motion, and the average number of these 263 
weak cross-links in the shear flow decreases when the shear rate is increased. While this 264 
characteristic is very desirable, it creates problems when attempting to measure the viscosity 265 
of HyA solutions and concentrated gels. A single-point viscosity test such as that typically 266 
conducted on a simple viscometer is insufficient to fully characterize the material. Instead of 267 
this, a viscosity/shear rate profile (such as that shown in Figure S4) is more suitable as a 268 
means of measuring this material. Moreover, we report the results of the dynamic 269 
measurements, which show the change of the loss and the storage modulus (G’ and G”) as a 270 
function of amplitude, under 10 s
-1
 oscillation frequency . All the samples were tested but 271 
only some results are presented for clarity. For the linear polymer (Figure 5), we observe the 272 
expected behavior. Polymer gels essentially show elastic character at low strain, while at high 273 
strain the loss modulus dominates (G” > G’). The distance between the G', and G'' curves has 274 
no such relevance as the ratio G''/G' which is equal to tan, this parameter is a measure of the 275 
internal friction of the material in that condition. 276 
 277 
Figure 5. Strain (A) and concentration (B) dependence of the viscoelastic parameters (storage 278 
modulus (solid symbols) and loss modulus (hollow symbols), flow point and phase angle) of 279 
linear HyA hydrogels. 280 
When G'' is higher than G', tan is the larger one we can say that the sample is more viscous 281 
than elastic, and when G' is higher and tan is the smaller one the sample shows an elastic 282 
property. Amplitude scans of the solvated linear HyA shows that the G''/G' ratio does not 283 
change as strain increases from 0.1 to 10.0%, it means that the internal friction is independent 284 
of strain in this region. Above strain value of 10%, the samples show non-linear dependence, 285 
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according to the pseudo-plastic or plastic behavior. The point where G'' crosses G' is denoted 286 
as the flow point, and above this strain value the viscous behavior dominates. Figure 5.B 287 
clearly shows that the flow points increase dramatically, while the phase angle decreases as 288 
the polymer concentration increases. The decrease of the phase angle indicates the change 289 
from Newtonian behavior to elastic behavior, which confirms viscoelastic fingerprint 290 
characterizing concentrated HyA solutions with weak gel-like behavior (Iannitti et al., 2013; 291 
Liang et al., 2007). 292 
3.3. Rheological characterization of the hydrophobized CTAB/HyA systems 293 
To characterize the hydrophobized form of the polymer, a constant (0.1 mg/mL) initial HyA 294 
concentration was chosen for the steady shear rate measurements of the CTAB solution 295 
diluted HyA samples and a larger concentration (50 mg/mL) was applied in the case of 296 
amplitude sweep investigations. As can be seen in Figure 6. the apparent viscosity of the 297 
polymer solution continuously decreases, due to the added surfactant, and a breakpoint can be 298 
observed on the viscosity vs. molar ratio (nCTAB /nmonomer) curve. After extraction the dilution 299 
effect only in the pre-break region can be observed. Above ca. 1:1 surfactant/monomer molar 300 
ratio, the viscosity of the neutralized and thus the hydrophobized polymer solution, shows a 301 
rising trend. After this observation it can be stated that in addition to conductivity and ITC 302 
measurement a modified rheological investigation also suitable for detection of the structural 303 
change of the polymer – surfactant colloid system. 304 
 305 
Figure 6. Steady shear rate determined apparent viscosity of linear HyA (cHyA = 0.1 mg/mL) 306 
titrated with CTAB (cCTAB= 25.0 mM) solution. 307 
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As illustrated in Figure 7. the varying degrees of hydrophobized polymer based hydrogels, 308 
show elasticity at low strain, while at high strain range the loss modulus dominates (G” > G’) 309 
as the above reported linear HyA hydrogels. As a result of added surfactant at 10 mg/mL 310 
CTAB concentration (20% of the neutralization needed surfactant amount) the flow point 311 
increased dramatically and it is slightly reduced by the effect of the following (50% and 80%) 312 
additional surfactant. The opposite tendency can be observed with regard to the change of 313 
phase angle value in the function of CTAB concentration. When the concentration of polymer 314 
is over the 50 mg/mL and surfactant is 10.0 mg/mL or lower the hydrogel becomes more 315 
elastic than without surfactant while above this surfactant amount the elastic behavior turns 316 
Newtonian. The same trend was observed in the case of varying degrees of cross-linked 317 
polymer hydrogels (Figure S5.) where the flow point almost reaches the zero value due to the 318 
structure modification of polymer chains, and the changes of phase angle showed a more and 319 
more viscous character. The latter outlined two observations confirm the assumption that both 320 
the added CTAB, and the cross-linking agent break the spontaneously formed coherent 321 
structure from the solvated biopolymer. 322 
 323 
Figure 7. Amplitude sweep determined rheological parameters (A: storage modulus and loss 324 
modulus; B: flow point and phase angle) of linear HyA hydrogels (cHyA = 50 mg/ mL) as a 325 
function of cCTAB. 326 
3.4 In vitro drug release experiments  327 
The detailed rheological characterization of the pure and modified drug carrier systems 328 
greatly contributes to the better understanding the mechanism of the drug release process. The 329 
mechanism of drug release from the HyA-based carriers was investigated using model-330 
dependent methods. The drug release results were fitted into first-order kinetics, Korsmeyer–331 
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Peppas and Weibull models. Drug release curves of KP from varying degrees of 332 
hydrophobized or cross-linked polymer-based carriers are depicted in Figure 8. As it can be 333 
seen, all the formulations are able to impede KP release for more than 6 h, but the release of 334 
the drug from the cross-linked polymer is almost complete within 7 h. In particular, the 335 
release kinetic of KP from cl-HyA/50% is the fastest and, above all, poorly controlled. By 336 
adding the linker from 50% to 75 and 100% into the polymer it was possible to achieve a 337 
more accurate control over drug release from the polymeric carrier. However, it should be 338 
noted that nearly 80% is released from the total drug content in the case of cl-HyA/100% at 339 
the end of the seventh hour (Figure 8A). On the other hand, using the least amount of 340 
surfactant (Figure 8B) caused only 60% of the active ingredient to dissolve during the 341 
experiment.  342 
 343 
 344 
Figure 8. Release profiles and Weibull kinetic model-predicted release curves of KP from 345 
varying degrees cl-HyA-based (A) and CTAB hydrophobized (B) drug carriers. 346 
Keeping regard the values of coefficient of determination, (R
2
) from Table 1, the Weibull 347 
model was the best and the Korsmeyer and Peppas model was the second best model for the 348 
hydrophobized polymer. While in the case of cl-polymers the Weibull model was the best, 349 
and first order model is the second best model for describing the release profiles.  Although 350 
the fitting of the Korsmeyer and Peppas equation does not produce a good description of 351 
dissolution profile as well as the Weibull model, the values of the matching parameters (km 352 
and n) also carry important information. Hydrophobized HyA exhibited a release exponent n, 353 
values of 0.60; 0.70 and 0.75, indicating that the drug release from surfactant – polymer 354 
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system might have followed both drug diffusion and the erosion of matrix in an anomalous 355 
non-Fickian manner.  356 
 Table 1. Fitting results of the experimental KP release data to different kinetic equations, for 357 
several formulations  358 
Release exponents of the cross-linked carriers are much closer to the limit (n = 0.45) which 359 
indicates the diffusion-controlled Fickian drug release. In addition, the fact that the value of 360 
the release exponent of the hydrophobized matrix continually decreases as the amount of 361 
surfactant increases, shows that the contribution of anomalous diffusion is gets stronger. 362 
Based on the observation of previous parts (change of the zeta potential, turbidity and particle 363 
size values as a function CTAB amount), it can also be established that the release of KP from 364 
the carrier faster and rather diffusion controlled when relatively small amount of electrostatic 365 
adsorbed surfactant molecules are present in the system. As the polymer-ionic surfactant 366 
interactions lead to changes in polymer structure the dissolution of the drug becomes slower, 367 
and the release turns to diffusion and erosion controlled way. 368 
4. Conclusion  369 
Since KP has some disadvantages as of low bioavailability and short half-life the 370 
formulation of controlled release dosage forms is needed. The results from both rheology and 371 
conductometric measurements verified the successful synthesis of two types of formulation by 372 
cross-linking of HyA or surface modification by CTAB. Turbidity, Zeta-potential and particle 373 
size analysis enabled the determination of optimal CTAB amount. The concentration-374 
dependent structure of the HyA-based carrier was clearly confirmed by several rheological 375 
investigations. The release mechanism of KP from each formulation tested was evaluated in 376 
light of the first-order, Korsmeyer–Peppas and Weibull kinetic models. The release of KP 377 
Formulation 
First-order Korsmeyer–Peppas Weibull 
k (h
-1
) R
2
 km (h
-n
) n R
2
 a b R
2
 
20% CTAB 0.16 0.9881 524 0.6039 0.9819 0.0003 0.7935 0.9971 
50% CTAB 0.10 0.9892 149 0.6975 0.9941 0.0002 0.8210 0.9978 
80% CTAB 0.04 0.9907 41 0.7484 0.9989 0.0001 0.7950 0.9995 
cl-HyA/50% 0.50 0.9995 1401 0.5539 0.9799 0.0001 0.9913 0.9995 
cl-HyA/75% 0.34 0.9977 698 0.6127 0.9783 0.0001 1.0095 0.9977 
cl-HyA/100% 0.26 0.9901 1126 0.5497 0.9886 0.0005 0.7950 0.9986 
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from the carrier is faster and rather diffusion controlled when relatively small amount of 378 
electrostatic adsorbed CTAB are present in the system. As the polymer-ionic surfactant 379 
interactions lead to changes in polymer structure the dissolution of drug becomes slower and 380 
the release turns to diffusion and erosion controlled way. However, the loading efficiency 381 
shows similar values (93-95%) but comparing the controlled drug release studies of our 382 
modified-HyA based systems with e.g. alginate-, gelatin- or acrylic polymer-based KP-383 
containing systems we can conclude that after 4-6 h all of the amount of the encapsulated 384 
drug was dissolved from the above mentioned composites while in case of our systems (e.g. 385 
cl-HyA/100%) after 7 h only 70% but for CTAB/HyA 50% ca. only 40% of the KP content 386 
was dissolved. These results support the better applicability of cl-HyA NPs instead of the 387 
above mentioned other biocompatible carriers. We presented a potential applications of 388 
effective HyA biomaterial-based colloidal controlled drug release systems which contain 389 
hydrophobic NSAID KP molecule.     390 
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